Rtw Investments, Lp - Aug 4, 2021 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: 10%+ Owner
Signature: RTW Investments, LP By: /s/ Roderick Wong
Stock symbol: RNA
Transactions as of: Aug 4, 2021
Transactions value $: $14,400,000
Form type: 4
Date filed: 8/6/2021, 11:20 AM
Previous filing: Jul 29, 2021
Next filing: Sep 7, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Purchase	$14.4M	+800K	+20.03%	$18.00	4.8M	Aug 4, 2021	By RTW	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Series C Preferred Stock	Conversion of derivative security		-4M	-100%		0	Jun 11, 2020	Common Stock	4M		By RTW	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The above-referenced shares (the "Shares") of Avidity Biosciences, Inc. (the "Issuer") reported herein are held in the form of common stock (the "Common Stock"). The Shares are held by RTW Master Fund, Ltd. and one or more funds (together the "Funds"), managed by RTW Investments, LP (the "Adviser"). The Adviser, in its capacity as the investment manager of the Funds, has the power to vote and the power to direct the disposition of all such Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 4,795,000 Shares, or 10.5% of the Issuer's 45,600,288 Shares deemed issued and outstanding as of August 4, 2021, as disclosed in the Issuer's Prospectus Supplement to its Prospectus dated July 2, 2021, as such supplement was filed with the Securities and Exchange Commission on August 3, 2021.
F2	The shares of Series C Preferred Stock are convertible, at any time, at the holder's election, at a ratio of one-for-2.1095 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series C Preferred Stock will automatically convert at a ratio of one-for-2.1095 shares of the Issuer's common stock. The Series C Preferred Stock has no expiration date.
F3	Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of the Adviser. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person's pecuniary interest therein.